Replies to post #42547 on Humanigen Inc (fka HGENQ)

[cowtown jay]

"The "significant expansion" of Milestone Events, beyond those regarding the partner-sponsored clinical trials for CMML, aGvHD, and CAR-T, could come from Sanofi and/or Novavax."

Today, Shah Capital filed an Amended 13D for their Novavax holdings.

"Item 4. Purpose of Transaction.


Item 4 is hereby amended to add the following:


On May 20, 2024, the Reporting Persons announced that in light of recent developments at the Issuer, they have determined to withdraw their preliminary proxy statement and campaign against the re-election of the Class II directors at the Issuer’s upcoming annual meeting. The Reporting Persons have long advocated for the Issuer to explore potential strategic partnership opportunities and believe that the Issuer’s recent announcement of its entry into a co-exclusive licensing agreement with Sanofi is a long-awaited step in the right direction."

https://www.sec.gov/Archives/edgar/data/1000694/000119380524000687/e663637_sc13da-novavax.htm

Sanofi, one of Humanigen's oldest shareholders (going back to Kalobios) has announced their intention to spin-off their healthcare division, and they and Novavax have acquired co-exclusive licenses to...use lenz as a vaccine enhancement? I believe so.

[cowtown jay]

"The Creditors’ Committee initially objected to the sale to Taran ..."

"On May 20, 2024, the Reporting Persons announced that in light of recent developments at the Issuer, they have determined to withdraw their preliminary proxy statement and campaign against the re-election of the Class II directors..."

The two above statements apply to Humanigen/Taran, and to Novavax/Sanofi, respectively. They both represent an abrupt about-face from the opposition the creditors and investors had towards Humanigen and Novavax.

That's completely understandable. Humanigen's Unsecured Creditors were excited about the Asset Purchase Agreement (APA) in regards to monetizing Milestone Events, because that would be based on regulatory approval.

https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1075977&projectCode=HUM&docketNumber=235&source=DM

And Novavax investors were excited about the removal of the company's going concern status, based on the co-exclusive licensing agreement they obtained with Sanofi.

To see some of the biggest stakeholders in Humanigen and Novavax abruptly cease their opposition to the directions of these two companies, foretells their unfolding success, which has been all too obvious to some of us, for quite some time.